Development and validation of a Multigenomic Liquid Biopsy (PROSTest) for Prostate Cancer Detection
Evaluation of a novel transcriptomic tumor signature (PROSTest) as response biomarker for177Lu-PSMA therapy in advanced prostate cancer
With the prostate-specific antigen (PSA) test now considered a less-than-reliable screen for prostate cancer, a worldwide search is under way to find an inexpensive, minimally invasive, and more effective tool to replace what was once considered the gold standard biomarker.
Barbadian doctors said Friday they are on the verge of groundbreaking research on a test for the illness which they believe could significantly reduce the prostate cancer epidemic and remove the often-daunting rectal examination to find the disease.
Yale University, Wren Laboratories and the Barbados Cancer Society have teamed to screen over 500 Barbadian men for molecular signatures indicating the presence of prostate cancer.
Relative to prostate-specific antigen (PSA), our mRNA-based diagnostic emerges as a more dependable biomarker, with an accuracy rate exceeding 90%, and readily repeatable while providing real-time information.
The Wren PROSTest is a 27-gene blood biopsy biomarker delivering greater than 90% accuracy in diagnosing and monitoring prostate cancer.